Mineralys Therapeutics In... (MLYS)
9.68
0.56 (6.14%)
At close: Jan 15, 2025, 12:37 PM
Cashflow (Annual)
Get detailed ratio statement breakdowns, uncovering price to free cash flow ratio, price per earnings, and much more.
| Year | FY23 | FY22 | FY21 | FY20 |
| Net Income | -71.90M | -29.80M | -19.41M | -3.43M |
| Depreciation & Amortization | n/a | n/a | n/a | n/a |
| Stock-Based Compensation | 5.06M | 455.00K | 80.00K | 1K |
| Other Working Capital | -7.47M | 772.00K | 4.08M | 480.00K |
| Other Non-Cash Items | -6.87M | -649.00K | 684.00K | 482.00K |
| Deferred Income Tax | n/a | n/a | n/a | n/a |
| Change in Working Capital | -7.47M | 772.00K | 4.08M | 480.00K |
| Operating Cash Flow | -81.17M | -29.22M | -14.56M | -2.46M |
| Capital Expenditures | n/a | n/a | n/a | n/a |
| Acquisitions | n/a | n/a | n/a | n/a |
| Purchase of Investments | -347.97M | -71.76M | n/a | n/a |
| Sales Maturities Of Investments | 187.50M | 50.00M | n/a | n/a |
| Other Investing Acitivies | n/a | -21.76K | n/a | n/a |
| Investing Cash Flow | -160.47M | -21.76M | n/a | n/a |
| Debt Repayment | n/a | n/a | n/a | n/a |
| Common Stock Repurchased | n/a | -1.63M | n/a | -20.00K |
| Dividend Paid | n/a | n/a | n/a | n/a |
| Other Financial Acitivies | 516.00K | 129.65M | 23.81M | 3.83M |
| Financial Cash Flow | 203.25M | 128.02M | 23.81M | 3.83M |
| Net Cash Flow | -38.40M | 77.04M | 9.25M | 1.37M |
| Free Cash Flow | -81.17M | -29.22M | -14.56M | -2.46M |